CJC-1295

CJC-1295 is a synthetic peptide classified as a Growth Hormone-Releasing Hormone (GHRH) analogue. It is designed to stimulate the release of growth hormone (GH) from the pituitary gland. Unlike natural GHRH, which has a short half-life, CJC-1295 is modified to extend its activity in the body. This extended activity is achieved through the addition of a Drug Affinity Complex (DAC), which binds to albumin in the bloodstream, protecting the peptide from degradation and prolonging its circulation time. The mechanism of action involves binding to the GHRH receptor on pituitary cells, triggering a cascade of events that ultimately lead to the synthesis and secretion of GH.

The current research landscape surrounding CJC-1295 is limited, particularly in human subjects. A search of scientific literature reveals a relatively small number of publications directly focused on this specific peptide. One notable clinical trial, sponsored by ConjuChem, aimed to evaluate CJC-1295 in HIV patients with visceral obesity (Phase 2). This trial, with a planned enrollment of 120 participants, was ultimately terminated. The reasons for termination are not readily available in the public domain, making it difficult to assess the potential efficacy or safety signals observed during the study. Other research papers, while mentioning GHRH or related compounds, often focus on analytical methods for detection and quantification of these peptides in biological samples. For example, studies have explored immunoaffinity purification and liquid chromatography-high resolution mass spectrometry (LC-HRMS/MS) techniques for identifying GHRH in human plasma. Some papers explore the interaction of GHRH receptors with other compounds, such as cannabinoids.

The safety profile of CJC-1295 is not fully established due to the limited clinical data. The FDA adverse event reporting system (FAERS) contains a very small number of reports associated with CJC-1295. Of the reported events, none were classified as serious. The most common reactions included injection site abscess and instances where a recalled product was administered. It's important to note that these reports represent spontaneous submissions and may not reflect the true incidence of adverse events. The absence of serious adverse event reports in this limited dataset does not guarantee the safety of CJC-1295, particularly with long-term use or in specific populations.

The regulatory status of CJC-1295 is complex. It is not FDA-approved for any therapeutic indication. Furthermore, it is classified as a Category 2 substance, meaning it is banned from compounding by pharmacies. Despite this restriction on compounding, CJC-1295 remains unregulated in terms of personal possession and use. This regulatory ambiguity creates a situation where the peptide is accessible through various channels, often marketed for off-label purposes.

CJC-1295 is often used by individuals seeking anti-aging effects, muscle growth, and improved body composition. These uses are primarily driven by anecdotal reports and marketing claims, rather than robust scientific evidence. Given the limited research and regulatory landscape, consumers should exercise caution and critically evaluate the available information before considering the use of CJC-1295. The lack of comprehensive clinical trials and the absence of FDA approval raise concerns about the potential risks and benefits associated with this peptide. Further research is needed to fully understand the long-term effects and safety profile of CJC-1295, and a clearer regulatory framework would help ensure consumer safety.